(Progress of Disclosures) Notice Regarding Completion of Full Acquisition and Absorption-type Merger of Renalis Pharma Co., Ltd.

Overview of Organizational Restructuring

Chugai Pharmaceutical Co., Ltd. acquired full ownership of Renalis Pharma Co., Ltd. on November 27, 2025, and subsequently completed an absorption-type merger on December 30, 2025, with Chugai Pharmaceutical Co., Ltd. as the surviving company and Renalis Pharma Co., Ltd. as the absorbed and dissolved company. Legally, this merger followed the full acquisition, with the effective date being December 30, 2025. Details were disclosed in the notice 'Notice Regarding Absorption-type Merger of Full Subsidiary (Renalis Pharma Co., Ltd.)' dated November 18, 2025.

Purpose and Background of the Restructuring

This organizational restructuring aims to enhance group management efficiency and promote business integration through the full acquisition and absorption-type merger of Renalis Pharma Co., Ltd. This enables unified business operations, optimal allocation of management resources, and acceleration of decision-making.

Impact on Shareholders and Investors

There is no description regarding changes in capital structure or dividend policy resulting from the absorption-type merger. The specific impact on consolidated financial results has not been disclosed and remains unknown. For investors, the strengthening of group business integration may potentially enhance corporate value in the future; however, no direct impact is indicated at this time.